Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
Revenue
Iterum Therapeutics PLC
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Perrigo Company PLC
NYSE:PRGO
|
Revenue
$4.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Revenue
$3.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
16%
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Revenue
$28m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
21%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Revenue
€96.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
See Also
What is Iterum Therapeutics PLC's Revenue?
Revenue
0
USD
Based on the financial report for Dec 31, 2023, Iterum Therapeutics PLC's Revenue amounts to 0 USD.